Dermorphin
A powerful opioid peptide first found in the skin of a South American tree frog. It's roughly 30–40 times stronger than morphine at the pain-relief receptor. Highly controversial because it was widely abused in horse racing — given to horses to mask pain and enhance performance — leading to doping scandals and animal welfare concerns.
Dosage
Not for human use — research reagent only
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Research use only (injection)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Pain Relief
30-40x more potent than morphine — extremely powerful pain suppression.
Mechanism of Action
Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a naturally occurring opioid heptapeptide first isolated from the skin of South American phyllomedusid tree frogs (Phyllomedusa sauvagei) in 1981. It is remarkable for containing a D-amino acid (D-alanine at position 2), a feature extremely rare in naturally occurring animal peptides and previously thought to be exclusive to bacterial peptides. This D-amino acid substitution is the key to both its extraordinary potency and stability.
Dermorphin is a highly selective agonist of the μ-opioid receptor (MOR/OPRM1), binding with 30-40 times greater affinity than morphine. MOR is a Gi/o-coupled GPCR — upon activation, it inhibits adenylyl cyclase (reducing cAMP), opens G protein-coupled inwardly rectifying potassium channels (GIRK), and closes voltage-gated calcium channels. The net effect on neurons is hyperpolarization and reduced neurotransmitter release. In pain pathways, MOR activation in the dorsal horn of the spinal cord inhibits ascending nociceptive signals, while activation in the periaqueductal gray and rostral ventromedial medulla activates descending pain inhibition pathways. In the reward system, MOR activation in the ventral tegmental area disinhibits dopaminergic neurons projecting to the nucleus accumbens, producing euphoria.
The D-alanine at position 2 is critical because it prevents cleavage by aminopeptidases and dipeptidyl peptidases that would rapidly degrade an L-amino acid peptide. This resistance to enzymatic degradation gives dermorphin a significantly longer half-life than endogenous opioid peptides like enkephalins (which are degraded within seconds to minutes). Combined with its extreme MOR selectivity and potency, this stability makes dermorphin pharmacologically powerful but also highly dangerous — the same properties that make it effective for analgesia create significant potential for respiratory depression, physical dependence, and fatal overdose. Its notoriety stems primarily from illicit use in horse racing, where it was administered to racehorses as an undetectable analgesic/performance enhancer before specific assays were developed.
Regulatory Status
Not FDA approved. Not approved anywhere for human use. Banned by horse racing authorities worldwide. Schedule classification pending in several jurisdictions. Available as research reagent only.
Risks & Safety
Serious
extreme potency makes dosing errors potentially fatal, severe respiratory depression, high addiction and physical dependence potential, sedation and impaired consciousness.
Rare
respiratory arrest and death from overdose.
Compare Dermorphin With
Research Papers
19Published: February 25, 2026
AI Summary
The opioid receptor family comprises classical; MOP (mu/µ), KOP (kappa/k), DOP(delta/δ) receptors along with non-classical Nociceptin/Orphanin FQ (N/OFQ) peptide receptor (NOP). Expression on glial cells is controversial where there is a role for glia and opioids in pain processing and immunomodulation. Here we detail expression and function of opioid receptors in a wide range of establish...
Published: August 28, 2025
AI Summary
The neuropeptide's multifaceted involvement in various components of neural homeostasis impacts pain and behavioral regulation. One of the highly potent neuropeptides is dermorphin, extracted from the skin of the Amazon frog (Phyllomedusa sauvagei). The unique feature of dermorphin is the D-Ala residue in its sequence, which has inspired researchers to search for dermorphin analogs for use as p...
Published: July 24, 2025
AI Summary
Opioids are among the most effective drugs for treating moderate to severe pain. Unfortunately, opioid use, even short-term, can lead to addiction, tolerance, overdose, and respiratory depression. Therefore, efforts to design and develop novel compounds that would retain analgesic activity while reducing side effects continue unabated.
Published: May 11, 2025
AI Summary
The South American shamanic Kambô ritual involves applying the skin secretions of Phyllomedusa bicolor (giant monkey frog) to superficial burns for purported spiritual and therapeutic benefits. These secretions contain a complex mix of bioactive peptides, such as phyllocaerulein, phyllomedusin, phyllokinin, sauvagine, dermorphins, and deltorphins, that interact with diverse neurotransmitte...
Published: October 28, 2025
AI Summary
Burn injury-induced chronic pain is a highly debilitating condition that profoundly impacts the well-being of military veterans and the general population. Current pain management for burn injured patients mainly relies on central opioids, often causing sedation, addiction, and physical dependence. This study aims to investigate the effects of Dermorphin [D-Arg2, Lys4] (1-4) amide (DALDA), a pe...
Published: April 11, 2025
AI Summary
Small peptide hormones are widely used in sports as performance-enhancing substances, making it crucial to develop sensitive analytical methods for their detection in doping control analysis. Various factors significantly affect analytical sensitivity, such as the selection of ultra-performance liquid chromatography (UPLC) mobile phase, high-resolution mass spectrometry (HRMS) scanning modes, a...
Published: April 2, 2024
AI Summary
Diverse chemical and pharmacological strategies are currently being explored to minimize the unwanted side effects of currently used opioid analgesics while achieving effective pain relief. The use of multitarget ligands with activity at more than one receptor represents a promising therapeutic approach. We recently reported a bifunctional peptide-based hybrid LENART01 combining dermorphin and ...
Published: August 25, 2024
AI Summary
Cold injury or frostbite is a common medical condition that causes serious clinical complications including sensory abnormalities and chronic pain ultimately affecting overall well-being. Opioids are the first-choice drug for the treatment of frostbite-induced chronic pain; however, their notable side effects, including sedation, motor incoordination, respiratory depression, and drug addiction,...
Published: January 18, 2024
AI Summary
Paclitaxel, a frequently utilized chemotherapeutic agent, often gives rise to severe and distressing sensory neuropathy in patients undergoing chemotherapy. Unfortunately, current therapeutics for chemotherapy-induced neuropathic pain (CINP) demonstrate limited effectiveness and are burdened with the potential for central side effects such as sedation, respiratory depression, cognitive impairme...
Published: December 4, 2022
AI Summary
Opioid receptors are naloxone-sensitive (MOP [mu: μ], DOP [delta: δ], and KOP [kappa: κ]) and naloxone-insensitive Nociceptin/Orphanin FQ (N/OFQ) peptide receptor (NOP). Clinically, most opioid analgesics target MOP. Angiogenesis is the formation of new blood vessels and involves endothelial cell activation, proliferation, and migration.
Published: June 22, 2023
AI Summary
Finding the ideal antimicrobial drug with improved efficacy and a safety profile that eliminates antibiotic resistance caused by pathogens remains a difficult task. Indeed, there is an urgent need for innovation in the design and development of a microbial inhibitor. Given that many promising antimicrobial peptides with excellent broad-spectrum antibacterial properties are secreted by some frog...
Published: March 4, 2024
AI Summary
Abstract too short to summarize.
Published: July 30, 2022
AI Summary
The opioid system in the central nervous system regulates depressive-like behavior in animals. Opioid receptors and their endogenous ligands have been focused on as novel therapeutic targets for depression. We synthesized dermorphin (DRM)-dynorphin (DYN) analogs (DRM-DYN001-004) using the message-address concept concerning interactions with opioid receptors.
Published: May 14, 2022
AI Summary
Fentanyl derivatives (FENS) belongs to the class of Novel Synthetic Opioids that emerged in the illegal drug market of New Psychoactive Substances (NPS). These substances have been implicated in many cases of intoxication and death with overdose worldwide. Therefore, the aim of this study is to investigate the pharmaco-dynamic profiles of three fentanyl (FENT) analogues: Acrylfentanyl (ACRYLF),...
Published: January 20, 2022
AI Summary
Opioids targeting mu;μ (MOP) receptors produce analgesia in the peri-operative period and palliative care. They also produce side effects including respiratory depression, tolerance/dependence and addiction. The N/OFQ opioid receptor (NOP) also produces analgesia but is devoid of the major MOP side effects.
Published: October 29, 2022
AI Summary
Opioid receptors are divided into the three classical types: MOP(μ:mu), DOP(δ:delta) and KOP(κ:kappa) that are naloxone-sensitive and an additional naloxone-insensitive nociceptin/orphanin FQ(N/OFQ) peptide receptor(NOP). Studies to determine opioid receptor location and turnover variably rely on; (i) measuring receptor mRNA, (ii) genetically tagging receptors, (iii) labelling recep...
Published: April 22, 2021
AI Summary
The μ-opioid peptide (MOP) receptor is a member of the opioid receptor family and an important clinical target for analgesia. Measuring MOP receptor location and tracking its turnover traditionally used radiolabels or antibodies with attendant problems of utility of radiolabels in whole cells and poor antibody selectivity. To address these issues we have synthesized and characterised a no...
Published: May 28, 2021
AI Summary
Ongoing neuropathic pain is one of the most challenging clinical problems which have detrimental effects on a patient's life quality. Conventional therapies for chronic neuropathic pain majorly includes centrally acting analgesics. Unfortunately, the unceasing use of these drugs results in adverse effects, such as CNS in-coordination, respiratory depression and substance use disorder.
Published: September 1, 2021
AI Summary
Dermorphin is a heptapeptide with an analgesic potential higher than morphine that does not present the same risk for the development of tolerance. These pharmacological features make dermorphin a potential doping agent in competitive sports and it is already prohibited for racehorses. For athletes, the development of an efficient strategy to monitor for its abuse necessitates an investigation ...
Frequently Asked Questions
What is Dermorphin?
A powerful opioid peptide first found in the skin of a South American tree frog. It's roughly 30–40 times stronger than morphine at the pain-relief receptor. Highly controversial because it was widely abused in horse racing — given to horses to mask pain and enhance performance — leading to doping scandals and animal welfare concerns.
What is Dermorphin used for?
A powerful opioid peptide first found in the skin of a South American tree frog. It's roughly 30–40 times stronger than morphine at the pain-relief receptor. Highly controversial because it was widely abused in horse racing — given to horses to mask pain and enhance performance — leading to doping scandals and animal welfare concerns.
What is the dosage for Dermorphin?
No established human dosing. Research use only. Extremely potent — microgram quantities produce significant pharmacological effects. Not intended for human administration.
What are the side effects of Dermorphin?
Serious: extreme potency makes dosing errors potentially fatal, severe respiratory depression, high addiction and physical dependence potential, sedation and impaired consciousness. Rare: respiratory arrest and death from overdose.
How does Dermorphin work?
Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a naturally occurring opioid heptapeptide first isolated from the skin of South American phyllomedusid tree frogs (Phyllomedusa sauvagei) in 1981. It is remarkable for containing a D-amino acid (D-alanine at position 2), a feature extremely rare in naturally occurring animal peptides and previously thought to be exclusive to bacterial peptides. This D-amino acid substitution is the key to both its extraordinary potency and stability. Dermorphin is a highly selective agonist of the μ-opioid receptor (MOR/OPRM1), binding with 30-40 times greater affinity than morphine. MOR is a Gi/o-coupled GPCR — upon activation, it inhibits adenylyl cyclase (reducing cAMP), opens G protein-coupled inwardly rectifying potassium channels (GIRK), and closes voltage-gated calcium channels. The net effect on neurons is hyperpolarization and reduced neurotransmitter release. In pain pathways, MOR activation in the dorsal horn of the spinal cord inhibits ascending nociceptive signals, while activation in the periaqueductal gray and rostral ventromedial medulla activates descending pain inhibition pathways. In the reward system, MOR activation in the ventral tegmental area disinhibits dopaminergic neurons projecting to the nucleus accumbens, producing euphoria. The D-alanine at position 2 is critical because it prevents cleavage by aminopeptidases and dipeptidyl peptidases that would rapidly degrade an L-amino acid peptide. This resistance to enzymatic degradation gives dermorphin a significantly longer half-life than endogenous opioid peptides like enkephalins (which are degraded within seconds to minutes). Combined with its extreme MOR selectivity and potency, this stability makes dermorphin pharmacologically powerful but also highly dangerous — the same properties that make it effective for analgesia create significant potential for respiratory depression, physical dependence, and fatal overdose. Its notoriety stems primarily from illicit use in horse racing, where it was administered to racehorses as an undetectable analgesic/performance enhancer before specific assays were developed.
How is Dermorphin administered?
Dermorphin is administered via research use only (injection).
What is the half-life of Dermorphin?
The half-life of Dermorphin is 1-2 hours (more stable than endogenous opioid peptides).
Is Dermorphin legal?
Not FDA approved. Not approved anywhere for human use. Banned by horse racing authorities worldwide. Schedule classification pending in several jurisdictions. Available as research reagent only.
Related Peptides
Ara-290
A peptide derived from EPO (the hormone that boosts red blood cells) but engineered to keep only the tissue-protective effects — it doesn't increase red blood cells at all. It activates the body's repair receptors to protect tissues and regenerate nerves. Particularly promising for nerve damage and tissue injury from poor blood flow. People use it for diabetic nerve damage and similar conditions.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
BPC-157 + TB-500
A two-in-one product that pairs BPC-157 and TB-500 to target different healing pathways. BPC-157 focuses on gut, tendon, and ligament repair by supporting blood vessel growth and nitric oxide signaling, while TB-500 helps cells move to injury sites for body-wide tissue repair. The most popular peptide combination for healing and recovery.
GHK-Cu
A naturally occurring copper-binding peptide found throughout the body; levels drop after age 20. The most studied cosmetic peptide, with proven effects on collagen production, skin renewal, wound healing, and antioxidant protection. It influences over 4,000 genes, shifting them toward a younger, more regenerative pattern. People use it for skin aging, wound healing, and anti-aging.